Loading
A phase 3 trial of Petosemtamab in head and neck squamous cell carcinoma, run by Merus B.V., active and no longer recruiting.
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) is a phase 3 interventional study registered as NCT06496178 by Merus B.V., with 621 participants enrolled, started 2024-06-25 and due to reach its primary completion in 2028-02. Interventions recorded: Petosemtamab, Investigator's Choice, Investigator's Choice, Investigator's Choice. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Petosemtamab, Genmab, Bispecific antibodies, Head and neck squamous cell carcinoma.
Shares Petosemtamab, Genmab, Recurrent or metastatic head and neck squamous cell carcinoma, Bispecific antibodies.
Shares Petosemtamab, Genmab, Bispecific antibodies.
Shares Petosemtamab, Genmab, Bispecific antibodies.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Bispecific antibodies, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/